15 January 2021
EMA/CHMP/6617/2021
EMEA/H/C/005388

Public statement

Qutavina

Withdrawal of the marketing authorisation in the European Union

On 24 November 2020, the European Commission withdrew the marketing authorisation for Qutavina (teriparatide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, EuroGenerics Holdings B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Qutavina was granted marketing authorisation in the EU on 27 August 2020 for the treatment of osteoporosis. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU since 2020.

Qutavina was a duplicate application to Livogiva, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Livogiva.

The European Public Assessment Report (EPAR) for Qutavina will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union